Pure erythroid leukemia is an aggressive form of acute leukemia, presenting with pancytopenia. It is defined as a neoplasm of erythroid lineage without a significant myeloblastic component, representing >80% of marrow, with 30% or more proerythroblasts. The disease has a rapid clinical course with median survival of only 3 months.
First described by Giovanni Di Guglielmo in the early 1920s, pure erythroid leukemia (PEL) is a neoplasm of erythroid lineage without a significant myeloblastic component, representing >80% of marrow cellularity, with 30% or more proerythroblasts.
1
A 44-year-old woman with no previous history of myelodysplasia presented with progressive fatigue and was found to be pancytopenic with leukopenia(WBC 2.98 × 10 3 /μL) with absolute neutropenia(1.04 × 10 3 /μL), anemia(Hgb of 5.7 g/ dL), and thrombocytopenia (5 × 10 3 /μL). Peripheral smear showed circulating erythroid precursors ( Figure 1A ). The bone marrow was 100% cellular(B, insert), replaced by neoplastic erythroid precursors (>90%) and abnormal megakaryocytes( Figure 1B ). Erythroid precursors were predominantly distributed in an intrasinusoidal pattern ( Figure 1C ). Reticulin showed diffuse myelofibrosis (MF2/3; D). The early erythroblasts were negative for CD34 and positive for E-Cadherin ( Figure 1E,F) . CD117 was positive in occasional mast cells distributed throughout. A diagnosis of pure erythroid leukemia was rendered, and a Myeloid Seq ® NGS panel revealed
The biology of this neoplasm is largely unknown, and the disease has a rapid course with median survival of 3 months. 1, 2 Day 14 biopsy after induction was still involved (>90%) by residual disease. The patient succumbed to the disease after a subdural hemorrhage led to transtentorial herniation.
